Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis

[1]  S. Ladhani,et al.  Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021–March, 2022: a national, observational, test-negative, case-control study , 2022, The Lancet Infectious Diseases.

[2]  Gheyath K Nasrallah,et al.  Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants , 2022, The New England journal of medicine.

[3]  D. Skowronski,et al.  Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study , 2022, The Lancet Infectious Diseases.

[4]  H. D. de Melker,et al.  Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections , 2022, Nature Communications.

[5]  Gheyath K Nasrallah,et al.  Duration of immune protection of SARS-CoV-2 natural infection against reinfection , 2022, medRxiv.

[6]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[7]  M. Ma,et al.  Omicron subvariants escape antibodies elicited by vaccination and BA.2.2 infection , 2022, The Lancet Infectious Diseases.

[8]  R. Milo,et al.  Estimating disease severity of Omicron and Delta SARS-CoV-2 infections , 2022, Nature Reviews Immunology.

[9]  Reed J. D. Sorensen,et al.  Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis , 2022, The Lancet.

[10]  A. Nordström,et al.  Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden , 2022, The Lancet Infectious Diseases.

[11]  Gheyath K Nasrallah,et al.  Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar , 2022, medRxiv.

[12]  J. Dushoff,et al.  Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.

[13]  S. Bhatt,et al.  Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study , 2022, The Lancet.

[14]  Reed J. D. Sorensen,et al.  Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020–21 , 2022, The Lancet.

[15]  Gheyath K Nasrallah,et al.  Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.

[16]  S. Pilz,et al.  SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity , 2022, Environmental Research.

[17]  Xiaoping Zhou,et al.  Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19：a meta-analysis , 2022, Annals of medicine.

[18]  Samuel M. Ostroff,et al.  Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis , 2022, The Lancet.

[19]  Graham W. Taylor,et al.  Rapid increase in Omicron infections in England during December 2021: REACT-1 study , 2021, Science.

[20]  Y. Ge,et al.  Untangling the changing impact of non-pharmaceutical interventions and vaccination on European COVID-19 trajectories , 2021, Nature communications.

[21]  F. Dentali,et al.  Mucosal immune response in BNT162b2 COVID-19 vaccine recipients , 2021, eBioMedicine.

[22]  C. Murray,et al.  Forecasting the Trajectory of the COVID-19 Pandemic under Plausible Variant and Intervention Scenarios: A Global Modelling Study , 2022, SSRN Electronic Journal.

[23]  Suresh Kumar,et al.  Omicron and Delta variant of SARS‐CoV‐2: A comparative computational study of spike protein , 2021, Journal of medical virology.

[24]  Jun Ma,et al.  Reinfection rates among patients previously infected by SARS-CoV-2: systematic review and meta-analysis , 2021, Chinese medical journal.

[25]  V. Simon,et al.  Efficient mucosal antibody response to SARS-CoV-2 vaccination is induced in previously infected individuals , 2021, medRxiv.

[26]  J. Klausner,et al.  A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection , 2021, medRxiv.

[27]  M. Keogan,et al.  Quantifying the risk of SARS‐CoV‐2 reinfection over time , 2021, Reviews in medical virology.

[28]  A. Ellebedy,et al.  SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans , 2021, Nature.

[29]  P. Klenerman,et al.  SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.

[30]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.

[31]  K. Mølbak,et al.  Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study , 2021, The Lancet.

[32]  S. Majumdar,et al.  A global panel database of pandemic policies (Oxford COVID-19 Government Response Tracker) , 2021, Nature Human Behaviour.

[33]  P. Kellam,et al.  T cell response to SARS-CoV-2 infection in humans: A systematic review , 2021, PLoS ONE.

[34]  M. Nussenzweig,et al.  Evolution of antibody immunity to SARS-CoV-2 , 2021, Nature.

[35]  T. Planche,et al.  Prior COVID-19 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months , 2021, Journal of Infection.

[36]  P. Bieniasz,et al.  Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients , 2020, The Journal of infectious diseases.

[37]  D. Cummings,et al.  A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity , 2020, Nature Communications.

[38]  Martin Linster,et al.  SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls , 2020, Nature.

[39]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[40]  N. Fullman,et al.  Pandemic Politics: Timing State-Level Social Distancing Responses to COVID-19 , 2020, medRxiv.

[41]  Peng Zheng,et al.  Trimmed Constrained Mixed Effects Models: Formulations and Algorithms , 2019, bioRxiv.

[42]  T. Vos,et al.  Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.

[43]  A. Charlett,et al.  Study quality assessment tools , 2016 .

[44]  M. Dijkers.  Living systematic reviews , 2014 .